Sign In
Buy BIAF
$1.69
+0.0100 (+0.595%)
At Close: Jun 03, 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--The Society for Advanced Bronchoscopy to host June 16 webinar featuring CyPath Lung's role in detection and management of early-stage lung cancer.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies receives notice of allowance for Mexican patent on methods of predicting the likelihood of lung cancer using flow cytometry.
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
09:15am, Tuesday, 12'th May 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today a
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
08:30am, Friday, 08'th May 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
09:16am, Tuesday, 28'th Apr 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AI--bioAffinity Technologies announces study with Brooke Army Medical Center to evaluate new diagnostic tests to improve treatment for asthma and COPD.
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
10:55am, Thursday, 16'th Apr 2026
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--Patient case study in which CyPath Lung spared a high-risk patient with a suspicious nodule and elevated risk from an invasive biopsy,.
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--CyPath Lung, bioAffinity Technologies' noninvasive test for lung cancer, will be featured at the Cleveland Clinic's annual lung cancer symposium.
bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
08:00am, Wednesday, 01'st Apr 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies' CyPath Lung Sales Surged 146% Year-Over-Year in Q1 2026, gaining traction in the U.S. addressable market of $3.58 billion.
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
08:00am, Wednesday, 25'th Mar 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will host a webinar on April 8 with leading pulmonologists who will share their clinical experience with CyPath Lung.
bioAffinity Technologies (BIAF) Projected to Post Quarterly Earnings on Monday
02:14am, Monday, 23'rd Mar 2026
bioAffinity Technologies (NASDAQ: BIAF - Get Free Report) will likely be announcing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in physician decision-making and patient outcome.
bioAffinity Technologies Stock Cools Off After Strong Friday Rally - Here's Why
08:35am, Monday, 16'th Mar 2026
bioAffinity Technologies Inc (NASDAQ: BIAF) stock falls in Monday premarket. Investors weigh 2025 revenue declines against surging CyPath Lung sales.
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
10:30am, Friday, 13'th Mar 2026
bioAffinity Technologies Inc (NASDAQ: BIAF) shares are trading sharply higher Friday morning after the company reported full-year 2025 results highlighting strong growth in its flagship CyPath Lung di
